– Medical device startup Cryosa from Singapore completed its Series B funding round, raising $21.5m.
РThe round was led by life sciences firm Solas BioVentures, with additional funding from Series A investors which include life sciences firm Sant̩ Ventures, global technology and med-tech company HOYA Corporation, and additional investors.
– The funding will be used to continue first-in-human clinical trials.

– EnteroBiotix is a biopharmaceutical company based in Glasgow, Scotland.
– The company raised $21m in Series A funding.
– The round was led by Thairm Bio with participation from Kineticos Ventures, Scottish Enterprise and SIS Ventures.
– The new investment will be used to advance the company’s microbiome drug pipeline and product development and manufacturing capabilities and grow its headcount to around 50.

– Intelligencia, whose AI-driven software platform enables pharmaceutical and biotechnology companies to revolutionize the drug development process and reduce risk, has raised $12M in order to continue to expand its product offering and customer base.
– Healthtech investor MTIP led the oversubscribed Series A round, joined by several of the company’s existing investors, including Big Pi Ventures and Synetro Group. ZS, a global professional services firm that leverages deep analytics and biopharmaceutical industry expertise to help companies and their customers thrive, has also participated in this round.
– The company’s founders, Dimitrios Skaltsas and Vangelis Vergetis, met while at McKinsey & Company, and have spent more than a decade in the intersection of clinical development, data science, and technology solutions.

– Reify Health announced a $220m Series C funding round led by Coatue Management, joined by ICONIQ Growth and Adams Street Partners, as well as existing investors Sierra Ventures and Battery Ventures.
– This latest funding, which brings the company’s valuation to $2.2bn, underscores Reify Health’s success in dramatically shortening clinical trial timelines.
– Reify Health has built a new foundation for how clinical trials are run through its business entities, StudyTeam and Care Access.
– StudyTeam delivers the best-in-class technology platform for optimizing patient recruitment and enrollment, and is used by top-20 global biopharma companies such as Amgen, AstraZeneca, and Eli Lilly and Company, and approximately 4,000 research sites across 65 countries.

– Castor, a leading provider of clinical trial software, announced the closing of a $45m Series B financing round.
– The round, led by Eight Roads Ventures and F-Prime Capital with participation from existing investors Two Sigma Ventures and Inkef Capital, will fuel continued product development with a particular focus on scaling direct-to-patient trials globally.
– Most clinical trials today require a long set-up time and are conducted at brick-and-mortar research sites which make trial participation inconvenient for patients and leave researchers in the dark about patient data in-between site visits.

– Lyndra Therapeutics from Watertown, MA develops a novel technology platform that transforms daily pills into once-weekly to monthly oral treatment options.
– The company closed a $60.5m Series C financing round.
– The round was led by new investor, AIG Investments, an affiliate of American International Group with participation from new investors Yipinhong Pharmaceutical (USA) Limited, Limitless Ventures and the Catalytic Impact Foundation with ImpactAssets, and existing investors Polaris Partners, Invus, Quark Venture, Mass General Brigham Ventures, HOPU Investments, and Gilead Sciences, Inc.

– Quanta Dialysis Technologies announced that it has raised $245m in an oversubscribed and upsized Series D round.
– The round was led by Glenview Capital and co-led by Novo Holdings, with support from a broad group of other top-tier investors.
– Quanta’s award-winning portable hemodialysis system SC+ is the only next-generation system that delivers the performance and dose equivalence of larger, traditional dialysis systems—with on-demand dialysate production and high dialysate flow rates—while also offering the portability, digital connectivity and ease-of-use of a next-generation dialysis device.
– The funding will allow Quanta to accelerate its emergence as a significant force in this market.

– Circle Pharma from South San Francisco develops macrocycle drug discovery and development company focused on intractable cancer targets.
– The company raised $66m in Series C financing.
– The round was co-led by The Column Group and Nextech Invest with participation from Pandect Bioventures, together with new investors including Euclidean Capital, Pavillion Capital, Hartford HealthCare Endowment and Eli Lilly and Company.
– The new investment will be used to advance its wholly owned cyclin-targeted programs towards the clinic.

– Hawthorne Effect, a San Francisco CA-based company which offers solutions for decentralizing clinical trials, raised $20M in Series A funding.
– The round was led by Northpond Ventures, with participation from SignalFire and P5 Health Ventures.
– The company intends to use the funds to accelerate growth and help scale operations.

– Mendel, the company behind the clinical AI platform that understands the unstructured, natural language content within medical documents, announced it has raised $18 million in Series A funding.
– The oversubscribed round was led by DCM, a global venture capital firm, with participation from OliveTree, Zola Global Investors and Millennium Technology Value Partners.
– Return investors include Launch Capital, SOSV, Bootstrap Labs and Chairman of UCSF Health Hub Mark Goldstein.
– Olive Tree Managing Partner, Nichola Eliovits, will join the board.
– The capital will help the company rapidly grow its business and sales team to keep up with the explosive demand for clinical AI technologies by healthcare organizations over the last year.

– Curebase today announced $15M in Series A funding to continue developing its decentralized clinical trial software platform and virtual research site capabilities, powering research where any patient, anywhere, can be part of clinical trials at home and with their own doctor.
– The financing was led by GGV Capital with participation from Xfund, Bold Capital, and several other institutional funds, and brings the total raised to $19M.
– Jeff Richards, managing partner, GGV Capital will join the board of directors.

– Mindful Health Solutions (MHS), a leading provider of interventional psychiatry and other mental health services, announced that it has closed a growth investment from Norwest.
– General Partner Dr. Ryan Harris and Principal Ryan McDonald will join MHS’ Board of Directors.
– Founded in 2007, Mindful Health Solutions (MHS) provides in-network mental health services, focused on improving clinical outcomes for patients with a wide range of conditions such as anxiety, depression, OCD, ADHD, PTSD, and memory disorders.
– MHS provides access to comprehensive mental health care, offering virtual and in-person Medication Management, talk therapy, Transcranial Magnetic Stimulation (TMS), Esketamine nasal spray, and other therapies via its extensive team of psychiatrists and psychiatric nurse practitioners.

– emocha Health, a digital health company which radically improves medication adherence amongst patients with chronic and infectious diseases, today announced the closing of a $6.2 million Series A funding round.
– The financing was led by Claritas Health Ventures and includes participation from Healthworx, the innovation and investment arm of CareFirst BlueCross BlueShield, Kapor Capital, and PTX Capital.
– emocha is the first company to comprehensively digitize the CDC-endorsed practice of Directly Observed Therapy — the gold standard for medication adherence, using a combination of two-way asynchronous video technology and human engagement powered by artificial intelligence.
– emocha is tackling one of the biggest unsolved challenges in healthcare – medication non-adherence, which results in $300 billion a year in preventable hospitalizations.

– Osage Venture Partners led the Series A financing round for Strategikon Pharma from San Francisco.
– Wing Venture Capital and Bascom Ventures also participated in the round.

– Qihan Biotechnology Co. Ltd, a leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, announced today that it has raised an additional $67 million in Series A++ financing.
– Proceeds from the financing will primarily be used to advance Qihan’s pipeline of novel cell therapies in IND-enabling studies and hypoimmunity projects, and expansion of the company’s GMP manufacturing facilities.
– The financing was backed by new investors including leading biomedical venture capital firm, Lilly Asia Ventures and Matrix Partners China, as well as existing shareholders, Sequoia and CMB International.
– With these investments, Qihan’s total Series A financing raised to date has exceeded $100 million.

– Bioheng Biotech raised $80m in Series B financing.
– The round was led by GL Ventures, the venture capital unit of Hillhouse Capital, Decheng Capital and Octagon Capital, with the participation of BlueRun Ventures and Shenzhen Capital Group Company.
– Proceeds will be used to advance R&D capabilities, process development and clinical trials.
– Bioheng is dedicated on developing novel cellular immunotherapy for cancer.

– UroGen Pharma Ltd. (Nasdaq: URGN) entered into a strategic funding agreement with RTW Investments, LP and its affiliated entities (“RTW”).
– Under the terms of the agreement, subject to customary closing conditions, UroGen will receive $75m in upfront cash from RTW in return for tiered, future cash payments based on aggregate worldwide annual net product sales of Jelmyto® (mitomycin) for pyelocalyceal solution as well as UGN-102, if approved.

– Cambridge Allergy Ltd (“Camallergy” or “the Company”), a biopharmaceutical company dedicated to providing innovative, patient-centric treatments for life-threatening food allergies, today announced it has been awarded £1.1M funding under the Innovate UK Biomedical Catalyst Award program administered by Innovate UK, the United Kingdom’s research and innovation agency.
– The £1.1M in non-dilutive funding will be used to accelerate the Company’s peanut allergy immunotherapy, CA002, for planned Phase 3 clinical trials.
– The project commences in the first quarter of 2021, and as part of the project’s success, the Company intends to file its investigation new drug application with the FDA and submit a clinical trials application to the MHRA and EMA.

– Medicortex Finland Oy, a Finnish biotechnology company focusing on brain injury diagnostics and drug development, announces receiving funding from the Finnish government innovation funding branch Business Finland.
– The funding is meant to expedite the development of a medical diagnostic test to improve detection of traumatic brain injury (TBI) and concussion.
– Medicortex has discovered novel biomarkers of head injury in body fluids such as saliva and urine.
– The objective of the company’s biomarker program is to generate new means for early detection of brain injury, which is a global unresolved issue.
– Current methods of brain injury diagnostics which are based on neurological examination and imaging do not reliably detect mild injury, yet they can have implications that are fatal or develop into a chronic condition if not recognized.

– TrakCel, a leading supplier of cellular orchestration solutions supporting the cell and gene therapy industry, today announces that it has closed its latest funding round led by AmerisourceBergen and Labcorp (NYSE: LH).
– These strategic investments enable further transformation of TrakCel’s cellular therapy orchestration solution, growth of its existing partner ecosystem, and continued global expansion.
– The company will use both the investment and the combined expertise gained from collaborations with the investors to further augment its offering to both clinical and commercial-stage cell and gene therapy developers as part of its drive toward industry standardization and future innovation.

– Clover Biopharmaceuticals, a global clinical-stage biotechnology company developing transformative biologics as vaccines and therapeutics for the world’s most debilitating diseases, today announced the completion of an oversubscribed $230 million Series C financing.
– This financing round brings Clover’s total capital raised in the last 12 months to over $400 million (over RMB 2.5 billion).
– The Series C round was co-led by GL Ventures and Temasek, with participation from Oceanpine Capital, OrbiMed and existing investor Delos Capital.
– The proceeds will support the continued development and expansion of Clover’s pipeline of protein-based vaccines and biologic cancer therapies utilizing its innovative and proprietary Trimer-Tag© technology platform.